Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2021

Rhea-AI Summary

Insulet Corporation (NASDAQ: PODD) will announce its fourth quarter and full year financial results for 2021 on February 23, 2022, after market close. A conference call with management is scheduled for 4:30 p.m. ET on the same day. The call will be accessible through the Investor Relations section of the company's website, and a replay will be available post-event. Insulet specializes in tubeless insulin pump technology under its Omnipod brand, offering innovative solutions for diabetes management and expanding to deliver non-insulin medications.

Positive

• Insulet is a leader in tubeless insulin pump technology.
• The Omnipod Insulin Management System offers unique features, providing up to three days of insulin delivery without needles.

Negative

• None.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2021 on February 23, 2022 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com/events, “Events and Presentations,” and will be archived for future replay. To participate in the live call via phone, please pre-register online here to receive a telephone number, passcode, and a unique registrant ID required to enter the call.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005017/en/

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

dgordon@insulet.com

Merrill Robichaud

Investor Relations Coordinator

(978) 932-0444

mrobichaud@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation

FAQ

When will Insulet Corporation report its financial results for 2021?

Insulet Corporation will report its financial results on February 23, 2022.

What time is the Insulet Corporation conference call scheduled?

The conference call is scheduled for 4:30 p.m. ET on February 23, 2022.

Where can I access the Insulet Corporation earnings call?

The earnings call can be accessed on the Investor Relations section of Insulet's website.

What is the Omnipod Insulin Management System?

The Omnipod Insulin Management System is a tubeless insulin pump that provides continuous insulin delivery without needles.